Latest News

Algos is an independent contract research organization specializing in preclinical in vivo pain research and program consulting. From experimental design and execution to data analysis, and from individual projects and consulting to program management, our rigorous processes and dedicated team deliver rapid and reliable results critical to drug discovery and product development. Through our commitment to customer service, we offer a flexible approach to both customized and standardized preclinical in vivo pain research that ensures our customers get the accuracy, speed, and reliability they need. Our experienced, customer-focused team of experts delivers exceptional value more cost-effectively than multi-sector preclinical CROs.
  • Oct 01
    Algos Attracts CRO Veteran Dr. Ganesh Iyer as its New CEO

    Algos Preclinical Services is pleased to announce Dr. Ganesh Iyer as its new president and CEO. Dr. Iyer will assume his new responsibilities immediately.

     “We were incredibly fortunate to have attracted such a uniquely qualified executive as Dr. Iyer to lead Algos.” stated Gary Smaby, Algos Board Chair and managing partner for Quatris Fund, the Company’s lead investor. “Dr. Iyer possesses the rare combination of scientific expertise and business acumen needed to lead Algos in the deployment of the Company’s new service-based CRO model focused on assisting leading pharmaceutical companies in bringing their technological breakthroughs to the marketplace.” adds Mr. Smaby.

    Until recently, Dr. Iyer was Director of Strategic Analysis and Business Operations at MDS Pharma Services. Dr. Iyer has over 16 years of strategic and business development experience with prominent biotech and high-tech companies ranging from R&D start-ups to F500 companies, including ZymoGenetics/Novo Nordisk, Xcyte Therapies, SkeleTech, MDS Pharma Services and Microsoft. Dr. Iyer holds a Ph.D. in Chemical Engineering from Purdue University and an M.B.A. from Seattle University.

     “I am very excited about joining Algos and look forward to working with an excellent team to achieving our mission and goal to become the premier preclinical in vivo pain research services company.” commented Dr. Iyer.

    2 Comments »
  • Aug 21
    Bola Taiwo, PhD hired as Director of Physiology

    Algos Preclinical Services continues to invest in critical personnel and equipment as a part of its ongoing program to enhance the company’s value proposition and as it completes its shift to a purely service based contract research organization. After significant investment in lab facilities and equipment, Algos has been able to consistently grow its pharmacology business. Algos is now able to expand its service portfolio by growing its physiology program. Dr. Dan Menard, CEO, summed it up when he said “We are leaders in behavioral pain pharmacology. It’s time to take the next step with our pain physiology group.” As a pivotal part of this initiative, Algos is pleased to announce the addition of Dr. Bola Taiwo to our leadership team.  Bola’s career spans both academic and commercial research. After obtaining his PhD in pharmacology, Bola pursued postdoctoral studies in Neuroscience at the University of Missouri-Kansas City and the University of Minnesota.  His research in the academia focused on the neurobiology of pain and analgesia, neuroimmunologic regulation of pain, and neurobehavioral studies of novel compounds with central nervous system targets.  After a stint in the academia, Bola joined Guidant Corporation (now Boston Scientific) where he served as Senior Scientist and Study Director in neurostimulation. More recently, Bola served as Study Director for cardiovascular, respiratory, and CNS safety pharmacology studies at Covance.  Dr. Taiwo will lead our growing physiology group.

    1 Comment »
    • « Older Entries